Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Lung Neuroendocrine Neoplasm: early-phase trial registry

2 of 4 indexed Lung Neuroendocrine Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Lung Neuroendocrine Neoplasm: 4 US clinical trials tracked, 2 recruiting.

Lung Neuroendocrine Neoplasm is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.

Enrollment posture brief

Registry condition lung-neuroendocrine-neoplasm

OPEN 2 | RECR 50% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Lung Neuroendocrine Neop (th…50%
Open-enrollment share among volume-matched conditions near Lung Neuroendocrine Neoplasm

Lung Neuroendocrine Neoplasm lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Neuroendocrine Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Neuroendocrine Neoplasm is recruiting above its size-band peers.

    2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 23

Phase Distribution

PhaseTrial count
Phase 2 3

Named interventions

Most-linked intervention names on Lung Neuroendocrine Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Computed Tomography Procedure
2 trials
Biospecimen Collection Procedure
2 trials
Incomplete Freund''s Adjuvant Biological
1 trials
Sargramostim Biological
1 trials
Lutetium Lu 177 Dotatate Drug
1 trials
Nivolumab Biological
1 trials
Fludeoxyglucose F-18 Other
1 trials
Everolimus Drug
1 trials

US sites by state

Facility locations filed on Lung Neuroendocrine Neoplasm trials. A trial with sites in several states counts in each.

Texas 2 trials
Minnesota 2 trials
Iowa 2 trials
Florida 2 trials
Wisconsin 1 trials
Utah 1 trials
Tennessee 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Neuroendocrine Neoplasm page

4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Neuroendocrine Neoplasm condition card totals 4 registered trials; most-linked intervention Computed Tomography; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.